Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 7/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 9/20 | 0.46 |
| ▸ | HTR7 | P34969 | 7/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12874629 | 0.85 | PIK3CA (0.49) | PIK3CAHTR5APLAUSLC9A1 | |
| SCHEMBL9909205 | 0.84 | HTR5A (0.42) | HTR5ASLC9A1 | |
| SCHEMBL9907815 | 0.84 | HTR5A (0.42) | PIK3CAHTR5APLAUHTR2BHTR7 | |
| SCHEMBL9907817 | 0.84 | HTR5A (0.53) | HTR5ASLC9A1HTR2BHTR7DRD2 | |
| SCHEMBL9907326 | 0.82 | PIK3CA (0.57) | PIK3CA | |
| SCHEMBL9909279 | 0.82 | HTR5A (0.44) | HTR5ASLC9A1 | |
| SCHEMBL9907801 | 0.81 | HTR5A (0.54) | HTR5ASLC9A1HTR2BHTR7 | |
| SCHEMBL9907794 | 0.81 | HTR5A (0.45) | HTR5APLAUHTR2BHTR7DRD2 | |
| SCHEMBL9909296 | 0.81 | HTR5A (0.45) | HTR5APLAUSLC9A1HTR2BHTR7 | |
| SCHEMBL9909209 | 0.81 | HTR5A (0.49) | HTR5ASLC9A1HTR2BHTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | PIK3CA 3492/4885HTR5A 1/4885PLAU 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.